Australian Clinical Labs Limited
Australian Clinical Labs Limited, commonly referred to as ACL, is a leading provider of pathology services headquartered in Australia. Established in 2003, the company has grown significantly, operating across major regions including New South Wales, Victoria, and Queensland. ACL specialises in a wide range of diagnostic testing services, including clinical pathology, genetic testing, and specialised laboratory services. Their commitment to innovation and quality sets them apart in the competitive healthcare landscape. With a strong market position, Australian Clinical Labs has achieved notable milestones, including strategic partnerships and expansions that enhance their service offerings. Their focus on delivering accurate and timely results has solidified their reputation as a trusted partner in the healthcare industry.
DitchCarbon Score
How does Australian Clinical Labs Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Australian Clinical Labs Limited's score of 32 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Australian Clinical Labs Limited's reported carbon emissions
In 2023, Australian Clinical Labs Limited reported total carbon emissions of approximately 61,890,000 kg CO2e for Scope 1, 24,414,000 kg CO2e for Scope 2, and 6,521,500 kg CO2e for Scope 3 emissions. The Scope 1 emissions primarily stem from direct operations, while Scope 2 emissions are associated with purchased electricity. Scope 3 emissions include significant contributions from business travel (about 1,160,200 kg CO2e) and fuel and energy-related activities (approximately 4,310,900 kg CO2e). In 2024, the company demonstrated a slight reduction in emissions, with Scope 1 emissions at about 5,878,000 kg CO2e, Scope 2 at approximately 24,402,000 kg CO2e, and Scope 3 emissions increasing slightly to around 6,529,200 kg CO2e. The business travel component rose to about 1,249,100 kg CO2e, while waste generated in operations decreased to approximately 868,300 kg CO2e. Despite these figures, Australian Clinical Labs Limited has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented climate pledges or science-based targets indicates a potential area for improvement in their sustainability strategy. The company’s emissions intensity for Scope 1 and 2 combined is reported at about 2.83 kg CO2e per employee in 2023 and 2.85 kg CO2e per employee in 2024, reflecting a stable operational efficiency in terms of emissions per workforce member.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 6,189,000 | 0,000,000 |
| Scope 2 | 24,414,000 | 00,000,000 |
| Scope 3 | 6,521,500 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Australian Clinical Labs Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
